Report DMCA Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care
* Please fill this form as much details as possible, we will respond to your request within 2 to 3 business days.
* Please fill this form as much details as possible, we will respond to your request within 2 to 3 business days.